Uncategorized

CHMP adopts positive opinion for severe alopecia treatment 

Published

on

Woman experiencing hair loss

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a treatment for severe alopecia. 

The recommended approval of upadacitinib is for the treatment of adult and adolescent patients with severe alopecia areata (AA), an unpredictable autoimmune disease causing a range of hair loss patterns. This can include sudden, round bald patches on the scalp to complete loss of all body hair, including scalp, face, eyebrows and eyelashes. 

The CHMP positive opinion follows data from the ongoing Phase III UP-AA clinical programme, with 15mg and 30mg doses meeting the primary endpoint, achieving 80% or more hair coverage compared to placebo. 

Upadacitinib is currently approved in the EU for the treatment of adults and adolescents with atopic dermatitis, and adults with radiographic axial spondylarthritis, non-radiographic axial spondylarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, and giant cell arteritis. Use of upadacitinib in AA is not currently approved in the EU.   

“Alopecia areata is an unpredictable autoimmune disease with underrecognised patient burden,” said Roopal Thakkar, Executive Vice President, Research and Development and Chief Scientific Officer at AbbVie, which developed the treatment. 

“The CHMP’s positive opinion for upadacitinib is a step closer to bringing a new treatment option to patients living with severe alopecia areata.”  

 

The post CHMP adopts positive opinion for severe alopecia treatment  appeared first on Drug Discovery World (DDW).

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version